SLC5A2 and type 2 diabetes mellitus: The findings of our review are in concordance with a recent meta-analysis investigating the efficacy and safety of bexagliflozin.47 They also suggest that bexagliflozin significantly impacts glycaemic management, thus reflecting the existing body of research on other commonly prescribed SGLT-2 inhibitors.51,52 Indeed, all SGLT-2 inhibitors have demonstrated comparable outcomes in terms of decreasing HbA1c levels in patients with T2D thus far.